INTRODUCTION
Hsp90 is an abundant, evolutionarily conserved molecular chaperone whose function depends on its ability to bind and hydrolyze ATP. Through an ATPase cycle, Hsp90 facilitates proper folding of 'client' proteins, thereby regulating their stability, protein interactions, intracellular trafficking, and functions. 1, 2 To fulfill these functions, Hsp90 interacts with its cofactors and cochaperones including Hsp70, immunophilins, and p23, to form the Hsp90-based chaperone complex. 1,2 Natural compounds such as geldanamycin and radicicol bind the ATP-binding pocket of Hsp90, and disrupt its chaperone function. 3, 4 Hsp90 is required for function and stability of diverse signal transduction proteins including oncogenic proteins such as ErbB2 and Raf-1. [2] [3] [4] [5] [6] [7] Hence, the chaperone is an attractive target of cancer therapeutics. Indeed, Hsp90 inhibitors show anti-tumor activities in pre-clinical models, and geldanamycin analogues such as 17-allylamino-17-demethoxygeldanamycin (17-AAG) are currently undergoing clinical trials. 3, 4 Importantly, Hsp90 inhibitors sensitize tumor cells to various genotoxic agents used for standard cancer therapeutics, including DNA crosslinkers, 8, 9 ionizing radiation, 10 and replication inhibitors. 11, 12 In line with these observations, it is suggested that Hsp90 regulates cell cycle checkpoints and DNA repair, [11] [12] [13] but the underlying mechanisms are poorly understood.
Fanconi anemia (FA) is a genetically heterogeneous inherited disorder characterized by progressive bone marrow failure, cancer susceptibility, and cellular hypersensitivity to DNA crosslinkers such as mitomycin C (MMC). [14] [15] [16] Multiple FA proteins cooperate in a common biochemical pathway, termed the FA pathway, which is involved in cellular response to DNA damage. At least eight FA proteins, i.e., FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL/PHF9, and FANCM form a nuclear multiprotein complex (FA core complex), which is required for FANCD2 monoubiquitination in response to DNA damage. 17- only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 32 DNA crosslinkers and replication inhibitors such as hydroxyurea (HU) are potent inducers of FANCD2 monoubiquitination. 14-16, The monoubiquitinated form of FANCD2 is targeted to the chromatin, and participates in maintenance of genomic stability interacting with BRCA1
and BRCA2/FANCD1, at least in part, through homology-directed repair.
25, [33] [34] [35] FANCJ/BRIP1, previously identified as a BRCA1-interacting helicase, may function downstream of FANCD2 activation or independently of the FA pathway. [36] [37] [38] Previous studies suggested that nuclear levels of FANCA have profound effects on FA core complex formation. [17] [18] [19] [20] 24, 25, 27 Nuclear levels of FANCA are determined by protein synthesis, degradation, and nucleocytoplasmic shuttling mediated by a bipartite nuclear localization signal (NLS) and three leucine-rich nuclear export signals. 18, 39, 40 However, little is known on the regulatory mechanisms for intracellular turnover and trafficking of FANCA.
In an attempt to elucidate the molecular mechanisms of the FA pathway, we found that Hsp90 was included in the FANCA-containing protein complex. The goal of the present study was to elucidate the molecular basis and functional significance of this interaction. We here provide evidence indicating that Hsp90 functions as a chaperone of FANCA and that Hsp90 promotes activation of the FA pathway through regulation of FANCA, which is critical for cellular tolerance to DNA crosslinkers. These findings reveal that the FA pathway is involved in the Hsp90-mediated regulation of DNA damage response.
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For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From
MATERIALS & METHODS
Plasmids. Human FANCA cDNA with a FLAG-HA tandem-tag at the N-terminus (FH-FANCA) was inserted into a retroviral expression vector pLPCX (Clontech). An expression vector for HA-tagged ubiquitin was previously described. 25 Human FANCA cDNA and FANCG cDNA were cloned into pcDNA3 Myc vector 41 or pcDNA3 (Invitrogen).
Cell culture and transfections. FANCA-null SV40-immortalized fibroblasts GM6914, MCF7, 293T, NIH3T3, and HeLa cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum. K562, Jurkat and RPMI8226 cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum. HeLa cells stably expressing FH-FANCA (HeLa/FH-FANCA cells) were obtained using a recombinant retrovirus as described previously. 27 A clone with appropriate expression of FH-FANCA (~5-fold of endogenous FANCA) was used for the present study. GM6914 cells stably expressing FANCA proteins were generated as described previously. 20 19 and rabbit polyclonal anti-FANCA 19 antibodies were previously described.
Protein identification by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis. HeLa/FH-FANCA cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% NP-40, 5 mM Na 3 VO 4 , 5 mM NaF) containing a protease inhibitor cocktail (Roche Diagnostics) for 1 h. After centrifugation at 16,000 X g for 30 min at 4°C, the supernatants were incubated with anti-FLAG M2-agarose at 4°C for 6 h. After extensive washing, the bound complexes were eluted with Tris-buffered saline containing 0.1 mg/ml of the FLAG peptide (Sigma) and digested with endoproteinase Lys-C. The resulting peptides were analyzed by an LC-MS/MS system at the femtomole level as described.
44,45
Immunoprecipitation and immunoblot analysis. Immunoprecipitation and immunoblotting were performed as described previously. 27 For detection of polyubiquitinated FANCA, cells were lysed in ubiquitin lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, only.
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Immunoprecipitated proteins and cell lysates were subjected to SDS-PAGE. Quantification pf protein signals were performed by densitometry using NIH Image software.
Immunofluorescence microscopy. Cells were immunostained as described previously.
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Cell nuclei were stained with a mounting medium containing 4', 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories). Fluorescence microscopy was performed as described previously.
Subcellular fractionation. Cytoplasmic and nuclear fractions were prepared from HeLa cells using CelLytic TM NuCLEAR TM extraction kit (Sigma) according to the manufacturer's protocol. Cytoplasmic and nuclear extracts were prepared as described.
In vitro binding assay. Myc-FANCA, Myc-FANCG and FANCA proteins were expressed in rabbit reticulocyte lysates (RRL) using the TNT T7 Quick Coupled Transcription/Translation System (Promega) according to the supplier's instructions. In vitro transcription/translation reactions were performed in a total volume of 50 µl for 90 min at 30°C, using pcDNA3 plasmids encoding the proteins. Reaction mixture was diluted with 500 µl of HEPES buffer (10 mM HEPES, pH. 7.6, 150 mM KCl, 10 mM MgCl 2 , 5 mM NaF, 20 mM Na 2 MoO 4 , 0.1% NP40) and the synthesized Myc-FANCA and Myc-FANCG were immunoprecipitated with an anti-Myc antibody, followed by immunoblot analyses. FLAG-tagged wild-type and truncated polypeptides of FANCA were synthesized in vitro, using DNA templates containing the T7 promoter and corresponding nucleotide sequences, and immunoprecipitated from the reaction using anti-FLAG antibody, followed by immunoblot analyses. 24 However, it should be noted that our experimental conditions were different from previous studies. 24 Most importantly, FANCAand FANCG-deficient cells were used in the previous studies, 24 whereas effects of the druginduced acute depletions of FANCA and FANCG were analyzed in the present study. Fig. 2C shows that 17-AAG induced decreases of FANCA protein levels in HeLa cells and MCF7
human breast cancer cells, in a dose-dependent manner within the range of 50-500 nM, which was consistent with known effective doses of the drug. 50 The dramatic effect of 17-AAG on FANCA protein levels suggested that FANCA might be a client of Hsp90. To confirm that the effect of 17-AAG was not cell-type specific, we examined the effect of the drug in other For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org 1 1 inhibitors radicicol and novobiocin, 4 showed similar effects on FANCA protein levels ( To further characterize the interaction between Hsp90 and FANCA, we determined the only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From subcellular localization of the FANCA/Hsp90 complex. Cell fractionation studies using HeLa/FH-FANCA cells (Fig. 5A) showed that the FANCA/Hsp90 complex was mainly detectable in the cytoplasm, whereas the FANCA/C/F complex was predominant in the nucleus, as previously described. 20, 23 Consistently, the association between Hsp90 and endogenous FANCA was mostly attributed to the cytoplasmic Hsp90/FANCA complex in parental HeLa cells (Fig. 5B) . These results suggest that the major target of Hsp90 is a cytoplasmic fraction of FANCA. Hsp90 and its cofactors such as Hsp70 and p23, which form the Hsp90-based multichaperone complex. In these reactions, FANCA associated with Hsp90 in a 17-AAG-sensitive manner, whereas FANCG did not (Fig. 5C , upper panels). When FANCA and FANCG were cotranslated in RRL, the two proteins formed a complex, which was not affected in the presence of 17-AAG (Fig. 5C , lower panels). Thus, contrary to the above hypothesis, the Hsp90 chaperone complex directly bound FANCA but not FANCG in vitro, and had little effect on the FANCA/G interaction.
To determine the region of FANCA which was responsible for the interaction with Hsp90, we expressed series of FANCA deletion mutants, and examined their interactions with Hsp90 in the same system. As shown in Fig. 5D , Hsp90 could interact with full-length, 1-1200, and 1-900 fragments of FANCA, whereas the binding of 1-600 FANCA to Hsp90 was drastically diminished, and no interaction was observed between 1-300 FANCA and Hsp90. The N- In a further attempt to identify amino acid residues responsible for interaction with Hsp90,
we examined association of Hsp90 with several patient-derived mutant proteins (H492R, H1110P, F1263del and W1302R), in which mutations were located on and surrounding the Hsp90-binding fragments of FANCA. These mutants, expressed in GM6914 FANCA-null cells, fail to complement the cells and enter the nucleus. 27 However, these mutations markedly enhanced interaction between Hsp90 and FANCA (Fig. 5E ). While these results may appear to be paradoxical to the notion that Hsp90 promotes FANCA, enhanced binding to client proteins with aberrant conformation is a physiological behavior of the chaperone.
Further work is required to elucidate the structural basis of the interaction between Hsp90 and FANCA. The previous observation that these mutant proteins interact with FANCG to a similar extent with the wild-type protein 27 further supports the above notion that FANCG and Hsp90 independently interact with FANCA.
Taken together, the above results suggest that Hsp90 stabilizes cytoplasmic FANCA in a FANCG-independent manner. To confirm this notion, we stably expressed ∆NLS FANCA mutant lacking an N-terminal region (amino acid residues 1-35) in GM6914 cells, and studied its turnover. The mutant protein fails to bind FANCG, and fails to enter the nucleus. 18, 20, 39 The results showed that the ∆NLS mutant was degraded at a similar rate to only.
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wild-type FANCA (Fig. 5E) . Unexpectedly, the basal half-life of the ∆NLS mutant protein was also similar to the wild-type protein. One explanation is that FANCG-binding plays a minor role in stability of the cytoplasmic pool, although it is required for maintaining total cellular levels of FANCA through stabilization of the FA core complex in the nucleus. Thus, Hsp90 and FANCG play distinct roles in cellular homeostasis of FANCA. Moreover, the drug suppressed FANCD2 monoubiquitination in HU-treated cells (Fig. 6C ).
17-AAG
FANCD2 monoubiquitination seems to be triggered by the formation of double-strand breaks (DSBs) during DNA replication after cellular exposure to DNA crosslinkers and replication inhibitors. 53 Thus, it could be possible that the 17-AAG-mediated suppression of FANCD2 activation was secondary to suppressed DSB formation due to the drug-induced growth arrest. To exclude this possibility, we examined the effect of 17-AAG on phosphorylation of a histone H2A variant H2AX, which is a sensitive marker of DSBs. 54 Immunoblot studies showed that 17-AAG treatment had little effects on MMC-or HU-induced increases of only.
For For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From cytotoxicity, but this effect was much less pronounced in GM6914 cells. To confirm these results, we determined percentages of apoptotic cells by TUNEL assay (Figs. 7C and D) . 17-AAG significantly increased MMC-induced apoptotic cells in GM6914/FANCA cells, but this effect was not seen in GM6914 cells (Fig. 7C) . Together, these results suggest that the effect of 17-AAG depends on the presence of an intact FA pathway.
FA pathway-defective cells characteristically show a high frequency of chromosomal aberrations after exposure to DNA crosslinkers. [14] [15] [16] Our results show that chromosome aberrations were detected in a small fraction of HeLa cells after exposure to DNA crosslinkers or 17-AAG, whereas percentages of cells containing chromatid breaks markedly increased after combined treatment with DNA crosslinkers and 17-AAG (Fig. 7E) . However, radial chromosomes, typical aberrations observed in FA cells, were not detected in these cells.
One likely explanation is that Hsp90 inhibition suppresses other DNA repair pathways through which DNA crosslinker-induced DSBs are misrepaired to generate radial chromosomes. 14 To support this notion, activation of DNA-dependent protein kinase, a critical component for nonhomologous end joining, is suppressed by Hsp90 inhibitors.
13

DISCUSSION
In the present work, we have demonstrated that the Hsp90 chaperone machinery regulates the As illustrated in our model (Fig. 7F) , the present work provides several new insights into the regulation of turnover and trafficking of FANCA. First, the disruption of the interaction between Hsp90 and a cytoplasmic fraction of FANCA rapidly induces a large reduction of total cellular levels of FANCA, despite its predominant localization in the nucleus. One explanation is that a nuclear pool of FANCA is rapidly exchangeable with a cytoplasmic pool which is in continuous dynamic cycles of assembly/disassembly with Hsp90 to be protected from proteolysis. To support this notion, nucleocytoplasmic shuttling of FANCA was recently reported. 40 only.
